Pyxis Oncology - Recently reported positive preliminary data from Phase 1 dose escalation trial of micvotabart pelidotin (“MICVO,” formerly PYX-201),...
Quarter
- PROSERA Phase 3 in PAH on Track for Topline Data Readout in Fourth Quarter of 2025 - - Registrational...
Conference call begins at 4:30 p.m. Eastern time today MIAMI, Feb. 27, 2025 (GLOBE...
NEW YORK, March 04, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical...
February 12, 2025 6:54 PM EST | Source: InMed Pharmaceuticals Vancouver, British Columbia--(Newsfile Corp. - February 12, 2025) -...
CAMBRIDGE, Mass., Dec. 18, 2024 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a late-stage clinical biotechnology company developing novel...
